The FDA on Jan. 14 approved AbbVie’s Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children 12 and older who have not responded to previous treatments. The JAK inhibitor was approved for daily use in both its 15mg and 30mg strengths, which could give it a competitive edge. For the treatment of rheumatoid arthritis, Rinvoq currently holds covered or better status for 96% of all insured lives under the pharmacy benefit. 37% of covered lives have preferred access to Rinvoq.
SOURCE: MMIT Analytics, as of 1/19/22